NuvOx Pharma Awarded NIH Grant to Develop Technology to Increase Sensitivity and Specificity of Breast Cancer Diagnosis
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, “B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant, said, “This project draws upon NuvOx’s expertise in nanotechnology to more specifically and effectively diagnose [PR.com]
More From Around the Web
Check out these Articles
- Global Potential Analysis of Ebola Drug and Vaccines (Pipeline Analysis, Dr...
- AstraZeneca upgrades sales and profit forecasts
- Pfizer/AstraZeneca: prescription for failure | Editorial
- Bill to ban investor-state dispute settlements garners support
- Martin Shkreli calls arrest ‘real injustice’ and blames it on A...
- Shire rejects £27bn takeover bid from US rival AbbVie
- Italian billionaire Stefano Pessina to make £4.45bn from Boots merger
- Pfizer’s initial offer for AstraZeneca is plainly dead in the water |...
- VIRUN® NutraBIOsciences™ Granted Patent 261124 in India, Redesigns Websi...
- Nine ways funding for the global HIV response could go further
- Merck pays £1.6bn for AZ Electronic Materials
- Patent nonsense of big pharma costs lives | Letter: Tony Greenstein
- MCS Achieves kCura’s Relativity “Best in Service” Designation
- AstraZeneca and the tyranny of shareholders | Gordon Roddick
- Agenda Released for the 11th Pharmaceutical Logistics Conference
- Shire clinches $32bn takeover of Baxalta
- Arkansas bought execution drugs from British company that banned state̵...